Novo Nordisk A/S

The AI in Biotechnology Market is projected to grow from USD 2.10 Bn in 2024 to USD 7.11 Bn by 2031, at a CAGR of 19%. Key opportunities include increased diagnostic accuracy, personalized therapies, revolutionized drug discovery, advanced genomic analytics, and integrated healthcare systems. Major players analyzed include AstraZeneca, Bristol-Myers Squibb, and Gilead Sciences Inc.

Bristol Myers Squibb's schizophrenia drug, Cobenfy, approved by FDA after 30-year journey from Eli Lilly's Alzheimer's drug xanomeline, could inspire future drug discovery.

AI in medicine market to grow from $8.01B in 2023 to $42.11B in 2028 at a CAGR of 39.3%, driven by chronic disease prevalence and digital transformation adoption.

Novo Nordisk's Phase II failure with CB1 blocker monlunabant highlights poor weight loss and neuropsychiatric adverse events, intensifying pressure on the company to acquire an oral obesity therapy.

The US Federal Trade Commission sued CVS Health Corp., Cigna Group, and UnitedHealth Group Inc., accusing their pharmacy benefit managers of illegal rebate programs that inflated insulin prices. The FTC alleges that Caremark, Express Scripts, and Optum Rx accepted drugmakers' money to keep lower-cost insulin off their approved lists, shifting more costs onto patients. The PBMs defend their practices, arguing they protect consumers from rising drug costs, while the FTC aims to lower list prices for insulin and other drugs.

The global Biotechnology Market is projected to reach USD 6.24 trillion by 2032, driven by R&D investments, healthcare demand, and advancements in pharmaceuticals, agriculture, and environmental management.

DelveInsight's 'Hemophilia B Pipeline Insight, 2024' report details the global Hemophilia B treatment market, including clinical trials, therapies, and company developments. Key companies and therapies in various stages of development are highlighted, along with market drivers and barriers.

Novo Nordisk executive Ulrich Otte anticipates Ozempic will likely face price negotiations with the US government, as part of Biden's Inflation Reduction Act, with CMS set to announce selected drugs for negotiation by February 1, 2025.

Personalized medicine market to reach $900.67 Bn by 2030, driven by cancer therapies and genetic tech. North America leads, emphasizing personalized nutrition and expanding therapeutic applications.